TG THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
TG THERAPEUTICS, INC. (TGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 0 shares for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2020-11-09
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2020-09-30 was 0.00 shares.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2020-06-30 was 0.00 shares.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2020-03-31 was 0.00 shares.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2019-12-31 was 0.00 shares.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2019 was 0.00 shares.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2017 was 887.59K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month |
|---|---|---|---|---|
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-09 | 0.00 shares 10-Q · filed 2020-11-09 | 0.00 shares derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 0.00 shares 10-Q · filed 2020-08-10 | 0.00 shares derived: sum of 3 quarters · filed 2020-08-10 | 0.00 shares derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2020-05-11 | 0.00 shares derived: sum of 3 quarters · filed 2020-05-11 | 0.00 shares derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-02 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-02 | 0.00 shares 10-K · filed 2020-03-02 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2019-11-12 | 0.00 shares 10-Q · filed 2019-11-12 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | 0.00 shares 10-Q · filed 2019-08-09 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-02 | |||
| 2017-12-31 | 887.59K shares 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |